Search research articles
Contact Us
Filters
Showing results (51-60 of 91) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Stroke (Hoboken, N.J.)
|
May 8, 2026
Sex-Dependent Manifestations of Intracranial Aneurysms
Thomas Wälchli, Martin Ndengera, Paul E Constanthin, et al.
Oncology Research and Treatment
|
November 25, 2015
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy
Oliver Gautschi, Carola Stadelmann, Franziska Aebersold-Keller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives
Julien Mazières, Solange Peters, Benoit Lepage, et al.
Clinical Lung Cancer
|
January 27, 2018
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Suresh S Ramalingam, Maurice Pérol, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
European Urology
|
April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
The Lancet. Oncology
|
June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
David R Gandara, Tomoya Kawaguchi, John Crowley, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 91) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Stroke (Hoboken, N.J.)
|
May 8, 2026
Sex-Dependent Manifestations of Intracranial Aneurysms
Thomas Wälchli, Martin Ndengera, Paul E Constanthin, et al.
Oncology Research and Treatment
|
November 25, 2015
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy
Oliver Gautschi, Carola Stadelmann, Franziska Aebersold-Keller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives
Julien Mazières, Solange Peters, Benoit Lepage, et al.
Clinical Lung Cancer
|
January 27, 2018
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Suresh S Ramalingam, Maurice Pérol, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
European Urology
|
April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
The Lancet. Oncology
|
June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
David R Gandara, Tomoya Kawaguchi, John Crowley, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Page
of 10